17 apr: Selskabsmeddelelse nr. 03/2019 - Coloplast reagerer på FDA’s besl..
17 apr: Correction: Selskabsmeddelelse nr. 03/2019 - Coloplast reagerer p..
17-04-2019 10:01:21

Coloplast responds to FDA’s decision to remove Surgical Transvaginal Mesh as Treatment Option for Pelvic Organ Prolapse

Coloplast was informed yesterday by the FDA that the PMA for Restorelle DirectFix Anterior is not approved and the company must cease marketing and distribution immediately.

As a result, FDA regulations require that all anterior transvaginal synthetic mesh products, including Coloplast’s Restorelle DirectFix Anterior device, can no longer be commercialized in the U.S., effective immediately. Coloplast will work with the FDA and other relevant authorities to ensure the orderly removal of these devices from customer inventories.

In accordance with the FDA guidance, Coloplast recommends that women who have received transvaginal mesh for the surgical repair of pelvic organ prolapse should continue with their annual and other routine check-ups and follow-up care. There is no need to take additional action if you are satisfied with your surgery and are not having any complications or symptoms. However, any patient with questions or concerns should speak to her healthcare provider. Please refer to the full statement on the  FDA website.

Coloplast is disappointed by the FDA decision to remove surgical transvaginal mesh as a treatment option for women suffering from pelvic organ prolapse. Coloplast has been committed to working with the FDA on the 522 clinical studies to document the long-term efficacy and safety of the products.

  • “Our mission at Coloplast is making life easier for people with intimate healthcare needs. Pelvic organ prolapses (POP) can be a painful, embarrassing, and a debilitating issue for the women who suffer from it. While mesh sales to treat POP in women account for approximately 0.2% of our global revenue, we firmly believe that patients and their physicians should have a choice of therapies. We are disappointed with the FDA’s decision because it reduces the treatment options for women with POP. We remain committed to providing alternative therapies.” says CEO Kristian Villumsen, Coloplast.

Coloplast has alternative solutions for the same type of produts including tissue products as well as alternative procedures for pelvic organ prolapse. The FDA’s decision is limited to mesh for the transvaginal repair of pelvic organ prolapse and does not extend to mesh used to treat stress urinary incontinence.

CONTACTS

Lina Danstrup

Senior Media Relations Manager

+45 49 11 26 07

dklina@coloplast.com

Ellen Bjurgert

Vice President, Investor Relations

+45 49 11 33 76

dkebj@coloplast.com

Attachment

logo.png

Relateret indhold
16 maj - 
Aktier/åbning: Maersk Drilling og Rockwool følger trend..
07 maj - 
Tirsdagens aktier: Lettelse sendte Demant og Pandora ti..
07 maj - 
Aktier/middag: Demant topper grønt C25
Relateret debat
02 maj - 
Det bliver spændende, at se om kursen springe i luften ..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Vestas får ordre på 249 MW i Texas

20-05-2019 12:29:23
Vestas har modtaget en ny ordre på det amerikanske marked omfattende V120-2.2 MW-møller med en samlet kapacitet på 249 megawatt (MW).Aftalen er indgået med en god gammel kending i vindmølleproducentens kundekartotek, EDF Renewables, som også har valgt at indgå en femårig serviceaftale af typen AOM 5000 med Vestas.Det fremgår af en meddelelse fra det danske vindmølleselskab mandag.Møllerne skal ops..

Ryanairs overskud skrumper trods flere rejsende - NY

Relaterede nyheder
20-05-2019 08:49:39
Lavprisselskabet Ryanair havde i 2018 flere rejsende og en større omsætning. Alligevel kan selskabet ikke præsentere samme fine overskud som året før - tværtimod.Ryanair har et skævt regnskabsår og starter sine år fra 1. april. Derfor løber regnskabsåret fra 1. april 2018 til 1. april 2019.I den periode har Ryanair haft et overskud efter skat på 1,02 milliarder euro. Det svarer til lige over 7,6 m..

Aktier/tendens: DSV i fokus efter kapitalfonds milliardsalg

20-05-2019 08:14:56
Aktien i DSV vil få opmærksomhed fra åbningen mandag, efter at kapitalfonden Cevian fredag solgte alle sine aktier i transportkoncernen og dermed indkasserede rundt regnet 4 mia. kr.Kapitalfondens 6,9 mio. DSV-aktier blev af UBS solgt til 575 kr., hvilket var 20 kr. eller 3,4 pct. under lukkekursen torsdag før store bededag. Det er en "forventelig" rabat ved salg af aktieposter af den størrelse, v..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: DSV i fokus efter kapitalfonds milliardsalg
2
Danske: Storbank hæver Danske Bank-anbefaling men sænker Nordeas
3
Veloxis/Kempen & CO: Anbefaling indledes med "køb" - kursmål 4,00 kr.
4
Aktier/åbning: Ambu flyvende fra start og pres på Mærsk
5
Ambu indgår distributionsaftale med Cook Medical i USA

Relaterede aktiekurser

Coloplast B A/S 712,80 -0,5% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. maj 2019 13:20:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190514.2 - EUROWEB5 - 2019-05-20 13:20:22 - 2019-05-20 13:20:22 - 1 - Website: OKAY